AKTS
NASDAQAktis Oncology Inc.
Price$18.94-0.75 (-3.81%)
01:30 PM07:45 PM
News · 26 weeks60-75%
2025-12-142026-06-07
Mix1690d
- SEC Filings4(25%)
- Offering3(19%)
- Other4(25%)
- Insider2(13%)
- Earnings2(13%)
- Leadership1(6%)
Latest news
25 items- PRAktis Oncology to Present at the Jefferies Global Healthcare ConferenceBOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the "Company"), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will present at the Jefferies Global Healthcare Conference in New York, New York. The presentation will take place on Wednesday, June 3, 2026, at 4:20 p.m. ET. A live webcast of the presentations may be accessed via the Investors section of the Aktis website at investors.aktisoncology.com. An archived
- PRAktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing TumorsData to be presented across two posters at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingCombined results evaluating AKY-2519 across several B7-H3 expressing tumor types, including metastatic castration-resistant prostate cancer (mCRPC), suggest a potentially differentiated profile compared to approved radiopharmaceuticalsAktis to hold conference call on Wednesday, May 27, 2026, at 8:00 a.m. ET with leading clinical investigators, Oliver Sartor, M.D., and Timothy Yap, MBBS, Ph.D., to discuss results BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthroug
- SECSEC Form SCHEDULE 13G filed by Aktis Oncology Inc.SCHEDULE 13G - Aktis Oncology, Inc. (0002035832) (Subject)
- SECSEC Form 10-Q filed by Aktis Oncology Inc.10-Q - Aktis Oncology, Inc. (0002035832) (Filer)
- SECAktis Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Aktis Oncology, Inc. (0002035832) (Filer)
- PRAktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026Announced two-trial clinical development strategy for AKY-2519 enabling evaluation in multiple patient segmentsInitiated Phase 1b clinical trial of AKY-2519 in metastatic castration-resistant prostate cancer (mCRPC); expect preliminary data in 2027Announced AKY-2519 clinical imaging and dosimetry data presentation at upcoming 2026 ASCO Annual MeetingEnrolling patients with Nectin-4 expressing tumors in ongoing Phase 1b clinical trial of AKY-1189; expect preliminary data in first quarter 2027 BOSTON, May 11, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiop
- PRAktis Oncology to Present at the BofA Securities Health Care ConferenceBOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the "Company"), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will present at the BofA Securities Health Care Conference in Las Vegas, Nevada. The presentation will take place on Wednesday, May 13, 2026, at 10:00 a.m. PT. A live webcast of the presentations may be accessed via the Investors section of the Aktis website at investors.aktisoncology.com. An archived
- PRAktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)Clinical development strategy includes an mCRPC-dedicated Phase 1b trial in PLUVICTO®-naïve and -experienced patients, and a second Phase 1b basket trial in other B7-H3 expressing solid tumorsTwo-trial strategy enables evaluation of AKY-2519 in broader patient segments and efficient generation of indication-relevant data; preliminary mCRPC data expected in 2027 Aktis to hold conference call tomorrow, Tuesday, May 5, 2026, at 8 a.m. ET to discuss its clinical development strategy for AKY-2519 BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiop
- PRTwo River and Vida Ventures Extend Track Record of Company Creation and Value Realization Following the Candid Therapeutics' Acquisition by UCBTwo River, LLC ("Two River") and Vida Ventures ("Vida"), both part of the Bellco Health ecosystem, today acknowledged the announced acquisition of Candid Therapeutics ("Candid"), a privately held clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs), by UCB (Euronext: UCB), a global biopharmaceutical company, for up to $2.2 billion, including $2.0 billion upfront. Two River and Vida played central roles in the creation and early development of Candid. Two River, together with Third Rock Ventures, helped found Candid, continuing Two River's consistent track record of founding and scaling innovative biotech
- ANALYSTWilliam Blair initiated coverage on Aktis OncologyWilliam Blair initiated coverage of Aktis Oncology with a rating of Outperform
- INSIDERSEC Form 4 filed by Gormley Glenn4 - Aktis Oncology, Inc. (0002035832) (Issuer)
- INSIDERSEC Form 3 filed by new insider Gormley Glenn3 - Aktis Oncology, Inc. (0002035832) (Issuer)
- SECSEC Form 8-K filed by Aktis Oncology Inc.8-K - Aktis Oncology, Inc. (0002035832) (Filer)
- PRAktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of DirectorsBOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the "Company"), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced the appointment of Glenn Gormley, MD, PhD, as an independent director to its Board of Directors and co-chair of the Company's newly established Science and Technology Committee of the Board of Directors. "We are delighted to welcome Glenn to our Board as we continue to make significant progress toward upcoming clinical and corporate milestones," said Matthew Roden, PhD, President a
- SECSEC Form 10-K filed by Aktis Oncology Inc.10-K - Aktis Oncology, Inc. (0002035832) (Filer)
- PRAktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial ResultsProgressing vision to expand the reach of targeted radiopharmaceuticals to large patient populationsAnticipating multiple milestones in the next 12 months, including initiation of Phase 1b clinical trial of AKY-2519 in mid-2026 BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the "Company"), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) applications for the Company to proceed to a Phase 1b clinical trial
- ANALYSTH.C. Wainwright initiated coverage on Aktis Oncology with a new price targetH.C. Wainwright initiated coverage of Aktis Oncology with a rating of Buy and set a new price target of $30.00
- PRAktis Oncology to Present at Upcoming March Investor ConferencesBOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will present at the following investor conferences in March 2026. TD Cowen 46th Annual Health Care Conference Date & Time: Tuesday, March 3, 2026, at 1:10 p.m. ETLocation: Boston, MA Leerink Partners Global Healthcare ConferenceDate & Time: Monday, March 9, 2026, at 1:40 p.m. ETLocation: Miami, FL A live w
- PRAktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein RadioconjugateU.S. FDA Fast Track designation granted to AKY-11891 for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have progressed on or after prior systemic therapiesOngoing Phase 1b trial of AKY-1189 enrolling patients with locally advanced or metastatic urothelial cancer and several other Nectin-4 expressing tumor types BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced that the U.S. Food and Drug Administ
- ANALYSTAnalyst initiated coverage on Aktis Oncology with a new price targetAnalyst initiated coverage of Aktis Oncology with a rating of Overweight and set a new price target of $30.00
- ANALYSTBofA Securities initiated coverage on Aktis Oncology with a new price targetBofA Securities initiated coverage of Aktis Oncology with a rating of Buy and set a new price target of $34.00
- ANALYSTLeerink Partners initiated coverage on Aktis Oncology with a new price targetLeerink Partners initiated coverage of Aktis Oncology with a rating of Outperform and set a new price target of $31.00
- ANALYSTTD Cowen initiated coverage on Aktis OncologyTD Cowen initiated coverage of Aktis Oncology with a rating of Buy
- SECSEC Form SCHEDULE 13D filed by Aktis Oncology Inc.SCHEDULE 13D - Aktis Oncology, Inc. (0002035832) (Subject)
- SECSEC Form SCHEDULE 13D filed by Aktis Oncology Inc.SCHEDULE 13D - Aktis Oncology, Inc. (0002035832) (Subject)
AKTS FAQ
7 questionsWhat does Aktis Oncology Inc. do?
Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., develops, designs, manufactures, and sells radio frequency (RF) filter products for the mobile wireless device industry in the United States. It operates through two segments, Foundry Fabrication Services and RF Filters. The Foundry Fabrication Services segment provides engineering review services; and semiconductor wafer-manufacturing and microelectromechanical systems foundry services. The RF Filters segment consists of amplifier and filter products. It offers RF filters for mobile wireless devices, such as smartphones and...Where does AKTS stock trade?
Aktis Oncology Inc. (AKTS) is listed on NASDAQ.What sector and industry is AKTS in?
Aktis Oncology Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Aktis Oncology Inc. go public?
Aktis Oncology Inc. (AKTS) completed its IPO in 2026.What are analysts saying about AKTS?
Aktis Oncology Inc. has had 8 recent analyst actions on file. The most recent action was from William Blair: Outperform on 2026-04-29.What companies are similar to AKTS?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare AKTS side-by-side with any of them on Quantisnow.How can I track AKTS on Quantisnow?
Quantisnow aggregates Aktis Oncology Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AKTS to receive live email and push alerts on every new disclosure.